Interfraction interval does not affect survival of patients with non-small cell lung cancer treated with chemotherapy and/or hyperfractionated radiotherapy: A multivariate analysis of 1076 RTOG patients

被引:31
作者
Werner-Wasik, M
Scott, C
Graham, ML
Smith, C
Byhardt, RW
Roach, M
Andras, EJ
机构
[1] Thomas Jefferson Univ, Jefferson Med Coll, Dept Radiat Oncol, Philadelphia, PA 19107 USA
[2] Radiat Therapy Oncol Grp, Kimmel Canc Ctr, Philadelphia, PA USA
[3] Washington Univ, Radiat Oncol Ctr, St Louis, MO USA
[4] Tom Baker Canc Ctr, Calgary, AB, Canada
[5] Med Coll Wisconsin, Dept Radiat Oncol, Milwaukee, WI 53226 USA
[6] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA 94143 USA
[7] Radiol Associates Sacramento Med Grp, Sacramento, CA USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 1999年 / 44卷 / 02期
关键词
lung cancer; radiotherapy; hyperfractionation; chemotherapy; esophagitis;
D O I
10.1016/S0360-3016(99)00031-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: It was observed by Jeremic et al. that a shorter interfraction interval (IFI) was associated with an improved survival in patients (pts) with locally advanced non-small cell lung cancer (NSCLC) treated with hyperfractionated radiation therapy (HFX-RT), with or without chemotherapy (CT), Our analysis was undertaken to verify this hypothesis. Methods and Materials: Records of patients treated on 5 Radiation Therapy Oncology Group (RTOG) studies were reviewed, and an actual IFI, defined as a mean of all daily IFIs, was calculated, RT dose was 1.2 Gy BID to 69.6 Gy, The relationship between the length of IFI and the median survival time and incidence of esophagitis was investigated, Results: In 682 pts eligible for this analysis, a full dose of RT was delivered and at least 90% of all daily IFIs were available, The actual mean IFI was as follows: 4-4.9 h in 51% of pts; 5-5.9 h in 17%; 6-6.9 h in 28% and 7-8 h in 4%, In multivariate analysis, only lack of weight loss, use of CT, low nodal stage and good KPS, but not IFI (4-6 h vs, 6-8 h) were associated with an improved survival for all pts (p values: < 0.0001; < 0.0001; 0.006; 0.006, and 0.73, respectively), as well as for HFX-RT only pts, For the CT-HFX-RT pts, not enough data points are available for a meaningful analysis, Length of IFI did not influence the incidence of Grade 3 or higher esophagitis (p = 0.82), but use of CT was associated with a 12-fold greater risk of developing severe esophagitis (p < 0.0001). Conclusion: Length of IFI (4-6 h vs, 6-8 h) did not influence survival and acute complications incidence in pts with NSCLC treated in RTOG studies with HFX-RT to 69.6 Gy, Previously identified factors, such as use of CT, minimal weight loss, good KPS and low nodal stage, were confirmed again to be associated with a favorable prognosis in a multivariate analysis, Use of CT was associated with a 12-fold greater risk of developing severe esophagitis than HFX-RT alone, It appears that an IFI of 4-8 hr is acceptable in clinical practice for pts with NSCLC, treated with HFX-RT, (C) 1999 Elsevier Science Inc.
引用
收藏
页码:327 / 331
页数:5
相关论文
共 23 条
[1]  
BYHARDT RW, 1995, CANCER, V75, P2337, DOI 10.1002/1097-0142(19950501)75:9<2337::AID-CNCR2820750924>3.0.CO
[2]  
2-K
[3]  
COX DR, 1972, J R STAT SOC B, V34, P187
[4]   INTERFRACTION INTERVAL IS A MAJOR DETERMINANT OF LATE EFFECTS, WITH HYPERFRACTIONATED RADIATION-THERAPY OF CARCINOMAS OF UPPER RESPIRATORY AND DIGESTIVE TRACTS - RESULTS FROM RADIATION-THERAPY ONCOLOGY GROUP PROTOCOL 8313 [J].
COX, JD ;
PAJAK, TF ;
MARCIAL, VA ;
COIA, L ;
MOHIUDDIN, M ;
FU, KK ;
SELIM, H ;
RUBIN, P ;
ORTIZ, H .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1991, 20 (06) :1191-1195
[5]   A RANDOMIZED PHASE-I/II TRIAL OF HYPERFRACTIONATED RADIATION-THERAPY WITH TOTAL DOSES OF 60.0 GY TO 79.2 GY - POSSIBLE SURVIVAL BENEFIT WITH GREATER-THAN-OR-EQUAL-TO 69.6 GY IN FAVORABLE PATIENTS WITH RADIATION-THERAPY ONCOLOGY GROUP STAGE-III NON-SMALL-CELL LUNG-CARCINOMA - REPORT OF RADIATION-THERAPY ONCOLOGY GROUP 83-11 [J].
COX, JD ;
AZARNIA, N ;
BYHARDT, RW ;
SHIN, KH ;
EMAMI, B ;
PAJAK, TF .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (09) :1543-1555
[7]   CHANGES OF CELL PROLIFERATION CHARACTERISTICS IN A RAT RHABDOMYOSARCOMA BEFORE AND AFTER X-IRRADIATION [J].
HERMENS, AF ;
BARENDSEN, GW .
EUROPEAN JOURNAL OF CANCER, 1969, 5 (02) :173-+
[8]   Effect of interfraction interval in hyperfractionated radiotherapy with or without concurrent chemotherapy for Stage III nonsmall cell lung cancer [J].
Jeremic, B ;
Shibamoto, Y .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1996, 34 (02) :303-308
[9]   RANDOMIZED TRIAL OF HYPERFRACTIONATED RADIATION-THERAPY WITH OR WITHOUT CONCURRENT CHEMOTHERAPY FOR STAGE-III NON-SMALL-CELL LUNG-CANCER [J].
JEREMIC, B ;
SHIBAMOTO, Y ;
ACIMOVIC, L ;
DJURIC, L .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (02) :452-458
[10]   HYPERFRACTIONATED RADIATION-THERAPY (HFX RT) FOLLOWED BY MULTIAGENT CHEMOTHERAPY (CHT) IN PATIENTS WITH MALIGNANT GLIOMA - A PHASE-II STUDY [J].
JEREMIC, B ;
GRUJICIC, D ;
ANTUNOVIC, V ;
DJURIC, L ;
STOJANOVIC, M ;
SHIBAMOTO, Y .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1994, 30 (05) :1179-1185